# Relationship of obesity and intrauterine contraceptive expulsion

Lisa Harris, MD, PhD<sup>1</sup>; Angelina Gangestad, MD<sup>2</sup>; Paul Blumenthal, MD, MPH<sup>3</sup>; Melissa L. Gilliam, MD, MPH<sup>4</sup>; Jeffrey Jensen, MD, MPH<sup>5</sup>; Mitchell D. Creinin, MD<sup>6</sup> <sup>1</sup>University of Michigan, Ann Arbor, MI; <sup>2</sup>Case Western Reserve University, Cleveland, OH; <sup>3</sup>Stanford University, Palo Alto, CA; <sup>4</sup>University of Chicago, Chicago, IL; <sup>5</sup>Oregon Health & Science University, Portland, OR; <sup>6</sup>University of California, Davis, Sacramento, CA

### Introduction

Liletta<sup>®</sup>, a levonorgestrel 52 mg intrauterine system (IUS), is U.S. FDA approved for up to 6 years of use for contraception and is being investigated for up to 10 years of use.

Obese intrauterine contraceptive users have higher expulsion rates than non-obese users.

### Objective

Investigate the association of increasing obesity and expulsion risk with levonorgestrel 52 mg IUS use.

## Study Design

**ACCESS IUS (A Contraceptive Clinical Efficacy and** Safety Study of an IUS): a prospective, multi-center, Phase 3, open-label study at 29 U.S. sites.

- Entry criteria:
- Age 16-45 years
- Regular menstrual cycles (21-35 days when not using hormones; typical variation ≤5 days)
- Sexually active, plan IUS as primary contraceptive
- No limits on weight, BMI or parity
- Total Liletta enrollment: n=1,751
- Successful placement: n=1,714 (97.9%)
- Follow-up visits scheduled at 1, 3, 6 and every 6 months thereafter during which Investigators confirmed IUS presence.

# Study Analysis

- Study population for this analysis:
- Body mass index (BMI)  $\geq$  30 kg/m<sup>2</sup>
- At least one follow-up contact after IUS insertion
- Evaluations:
- Expulsion rates over time through 6 years in persons with BMI 30.0-39.9 kg/m<sup>2</sup> and  $\geq$ 40 kg/m<sup>2</sup> using Fisher exact tests
- Multivariable model to assess expulsion association in obese users (with BMI and parity as continuous variables); included BMI, Age, Race (white v. non-white), Ethnicity, Parity, Marital Status, History of Miscarriage, Baseline subjective heavy menstrual bleeding (HMB), Hormonal contraceptive use at enrollment

### **Participant Characteristics**

	Obese BMI $\geq$ 30 kg/m <sup>2</sup> N=431			Total N=431	BMI 30.0-39.9 kg/m <sup>2</sup> n=339	BMI ≥ 40 kg/m² n=92	P-value
BMI at enrollment (kg/m <sup>2</sup> )	36.4 ±5.9	<b>Expulsion Rate (cumulative)</b>	e)				
>40	92 (21.3)	One year		22 (5.1)	15 (4.4)	7 (7.6)	0.28
Age at enrollment (years)	28.5 ±6.1	Six years		31 (7.2)	21 (6.2)	10 (10.9)	0.17
<25	125 (29.0)						
25-45	306 (71.0)	Multivariable Analysis	No facto	ors significa	nt - 3 highest odds	s ratios pre	sented:
Race		Variable	Ν	Expulsion	Odds Ratio	Adjusted	Odds Ratio
White	297 (68.9)	BMI at enrollment				1.	05
Black	106 (24.6)	(continuous)				(95% CI (	).99-1.11)
Other	28 (6.5)	30.0-39.9 kg/m <sup>2</sup>	339	21 (6.2)	referent		
Ethnicity		≥40.0 kg/m <sup>2</sup>	92	10 (10.9)	1.85		
Hispanic/Latina	73 (16.9)				(95% CI 0.84-4.07)		
Nulliparous	174 (40.4)	Parity (continuous)				1.	33
Marital status						(95% CI (	).98-1.81)
Never married	253	Nulliparous	174	8 (4.6)	referent		
Married/ever married	178	Parous	257	23 (8.9)	2.04		
History of Miscarriage	71 (16.5)				(95% CI 0.89-4.67)		
Baseline HMB	54 (12.5)	Baseline HMB (categorica	)	2A(CA)			
Contraceptive at enrollment		INO Voc	З// БЛ	Z4 (6.4) 7 (12 0)	reterent	rete	erent
Levonorgestrel IUS	42 (9.7)	ies	54	7 (15.0)	2.13	۲. ۱۵۵% ۲۱ (	UJ 1 Q7 5 221
Copper IUD	9 (2.1)				(35/0  CI  0.03  - 5.50)	(9570 CTC	J.82-J.33J
Implant	2 (0.5)	Conclusions					
CHC	130 (30.2)	Although abaca lovar	orgotra		Sucorc ovnorionco	highor ovn	ulcion
POP	11 (2.6)	<ul> <li>Although obese levollorgestrer 52 mg los users experience higher expulsion rates than non-obese users, we did not identify a significant difference in expulsion risk as BMI increases when evaluating just obese women</li> <li>Deceling UMD merity and &gt; 40.0 kg (m2 meru be sees sisted with symulation on an and sees and sees sisted with symulation on an and sees and sees sisted with symulation of the second set of the second se</li></ul>					
Non-hormonal/Non-IUD	193 (44.8)						
None	44 (10.2)						

Data are presented as n (%) or mean ± standard deviation BMI: Body Mass Index; IUD: intrauterine device; CHC: combined hormonal contraceptive; POP: progestin-only pill

Study funded by Medicines360, a non-profit pharmaceutical company

#### Results

#### **Expulsion rates**

- obese levonorgestrel 52 mg IUS users; studies with even more obese participants are needed to further evaluate these potential associations

• Baseline HIVIB, parity and  $\geq 40.0$  kg/m2 may be associated with expulsion among